Post-marketing Surveillance and Evaluation of Chinese Drugs in the New Era

doi:10.19803/j.1672-8629.2020.10.01

Abstract

Abstract: Based on new missions, new ideas, new regulatory systems, and new situation regarding drug supervision, this article analyzes the opportunities and challenges facing post-marketing surveillance and evaluation of drugs in China. In view of the status quo in China and development worldwide, recommendations are offered as to how to improve the regulatory system quickly, continue to enhance the capabilities of monitoring and evaluation, work hard to prevent drug safety risks, research new post-marketing surveillance and evaluation methods, and establish highly efficient information systems.

Key words: post-marketing surveillance and evaluation of drugs, adverse drug reaction, Pharmacovigilance

CLC Number:

R969.3

SHEN Chuanyong, WU Tingting, LIU Wei, ZHENG Mingjie, FAN Rong, DONG Duo. Post-marketing Surveillance and Evaluation of Chinese Drugs in the New Era[J]. Chinese Journal of Pharmacovigilance, 2020, 17(10): 649-652.

References

[1] Xu F.Scientifically Grasp the Dialectical Thinking of The New "Drug Administration Law"[J]. China Food & Drug Administration Magazine(中国食品药品监管), 2019 (9):4-15.
[2] Xu F.Deeply Understand the Essence of The New "Drug Administration Law"[J]. China Food & Drug Administration Magazine(中国食品药品监管), 2019(10):4-19.
[3] Xu JH. Risk and Responsibility[N].China Food Safety News (中国食品安全报), 2015-06-30(A02).
[4] Yang Y .Implementation of Pharmacovigilance System in Drug Administration Law and Application of ICH E2 Guideline[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(2):65-71.
[5] National Medical Products Administration. National Medical Products Administration was Elected as a Member of The International Conference on Harmonization [EB/OL].(2017-06-22) [2020-07-13]. http://www.nmpa.gov.cn/WS04/CL2097/318606.html.
[6] National Medical Products Administration. National Medical Products Administration was Elected as a Member of The Administrative Committee of the International Conference on Harmonization [EB/ OL].(2018-06-07)[2019-05-06]. . National Medical Products Administration was Elected as a Member of The Administrative Committee of the International Conference on Harmonization [EB/ OL].(2018-06-07)[2019-05-06]. http://www.nmpa.gov.cn/WS04/ CL2056/228304.html.
[7] China Food and Drug Administration. Announcement on The Application of The Secondary Guidelines of The International Conference on Harmonization[EB/OL]. (2018-01-25) [2020-07-13]. http://www.nmpa.gov.cn/WS04/CL2138/300493.html.
[8] National Center for ADR Monitoring. Announcement on the Annual Report for National ADR Monitoring (2019)[EB/OL].(2020-04-10) [2020-07-13].http://www.cdr-adr.org.cn/tzgg_home/202004/ t20200410_47300.html.
[9] National Medical Products Administration. National Adverse Drug Reaction Monitoring and Evaluation Work Video Conference was Held [EB/OL]. (2020-05-19) [2020-07-13]. http://www.nmpa. gov.cn/WS04/CL2056/377524.html.
[10] Guo T. Nine Tasks for Drug Monitoring and Evaluation in2020 [N]. China Pharmaceutical News (中国医药报),2020-06-01(04).
[11] National Center for ADR Monitoring. Conference on Active Surveillance of Drug Safety was Held in Jinan [EB/OL].(2019-11- 05)[2020-07-13].http://www.cdr-adr.org.cn/center_news/201911/ t20191105_46714.html.
[12] The State Council The People's Republic of China. Notice of the State Council on Issuing the "13th Five-Year" National Food Safety Plan and the "13th Five-Year" National Drug Safety Plan [EB/OL].(2017-02-21)[2020-7-13].http://www.gov.cn/zhengce/ content/2017-02/21/content_5169755.htm.
[13] National Medical Products Administration. NMPA Launched China's Drug Regulatory Scientific Action Plan [EB/OL].(2019-04-30) [2020-07-13]. http://www.nmpa.gov.cn/WS04/CL2056/3371.
[14] National Medical Products Administration. NMPA Organized Video Conference on NRA Evaluation Work of Provincial Administration [EB/OL].(2020-03-31) [2020-07-13]. http://www.nmpa.gov.cn/ WS04/CL2053/376191.html.
[15] Ma J.Discussion the Application of Master Data Management in Drug Regulatory Taking the Construction of Drug Variety Files as an Example[J]. Chinese Pharmaceutical Affairs(中国药事), 2018,32(9): 1172-1175.